Mutagenesis of a single amino acid in the rat μ-opioid receptor discriminates ligand binding

Journal of Neurochemistry

Volumn 70, Issue 1, 1998, Pages 358-365

  Bot, George ^a   Blake, Allan D ^a   Li, Shuixing ^a   Reisine, Terry ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Agonists; Antagonists; Mutagenesis; Opioid receptor

Indexed keywords

BETA ENDORPHIN; BUPRENORPHINE; DIPRENORPHINE; ENKEPHALIN; ETORPHINE; METENKEPHALIN; MORPHINE; NALORPHINE; NALOXONE; SIGMA OPIATE RECEPTOR;

ARTICLE; BINDING AFFINITY; GENE EXPRESSION; HUMAN; HUMAN CELL; LIGAND BINDING; MUTAGENESIS; PRIORITY JOURNAL; RECEPTOR AFFINITY;

EID: 0031973007     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.1998.70010358.x     Document Type: Article

References (35)

1. Befort K., Tabbara L., Bausch S., Chavkin C., Evans C., and Kieffer B. (1996) The conserved aspartate residue in the third putative transmembrane domain of the δ-opioid receptor is not the anionic counterpart for the cationic opiate binding but is a constituent of the receptor binding site. Mol. Pharmacol. 49, 216-223.
2. Bentley K. W. (1971) The morphine alkaloids, in The Alkaloids, Vol. 13 (Manske R. F., ed), pp. 75-120. Academic Press, New York.
3. Blake A. D., Bot G., and Reisine T. (1997a) Structure-function analysis of the cloned opiate receptors: peptide and small molecule interactions. Chem. Biol. 3, 967-972.
4. Blake A. D., Bot G., Li S., Freeman J., and Reisine T. (1997b) Differential opioid agonist regulation of the mouse μ-opioid receptor. J. Biol. Chem. 272, 782-790.
5. Chan J. S. C., Chiu T. T., and Wong Y. H. (1995) Activation of type II adenylyl cyclase by the cloned μ-opioid receptor: coupling to multiple G proteins. J. Neurochem. 65, 2682-2689.
6. Chen C. A. and Okayama H. (1988) Calcium phosphate-mediated gene transfer: a high efficiency transfection system for stable transforming cells with plasmid DNA. Biotechniques 6, 632-638.
7. Costa E. M., Hoffman B. B., and Loew G. H. (1992) Opioid agonists binding and responses in SH-SY5Y cells. Life Sci. 50, 73-81.
8. Dray A., Nuna L., and Wire W. (1986) Meptazinol: unusual in vivo opioid receptor activity at supraspinal and spinal sites. Neuropharmacology 25, 343-349.
9. Foley K. M. (1993) Opioid analgesics in clinical pain management, in Handbook of Experimental Pharmacology, Vol. 104: Opioids II (Herz A., ed), pp. 697-743. Springer-Verlag, New York.
10. Heerding J., Raynor K., Kong H., Yu L., and Reisine T. (1994) Mutagenesis reveals that agonists and peptide antagonists bind in fundamentally distinct manners to the rat mu receptor than do nonpeptide antagonists. Regul. Pept. 54, 119-120.
11. Jiang Q., Mosberg H. I., and Porreca F. (1990) Modulation of the potency and efficacy of mu-mediated antinociception by delta agonists in the mouse. J. Pharmacol. Exp. Ther. 254, 683-689.
12. Katsumata S., Minami M., Nakagawa T. Iwamura T., and Satoh M. (1996) Pharmacological study of dihydroetorphine in cloned μ-, δ- and κ-opioid receptors. Eur. J. Pharmacol. 291, 367-373.
13. Kaufman D. L., Keith D. E., Anton B., Tian J., Magendoz K., Newman D., Tran T. H., Lee D. S., Wen C., Xia Y.-R., Lussis J. A., and Evans C. J. (1995) Characterization of the murine μ opioid receptor gene. J. Biol. Chem. 270, 5877-5883.
14. Kenakin T. (1995) Agonist-receptor efficacy. I. Mechanisms of efficacy and receptor promiscuity. Trends Pharmacol. Sci. 16, 188-192.
15. Kong H., Raynor K., Yasuda K., Moe S. T., Portoghese P. S., Bell G. I., and Reisine T. (1993) A single residue, aspartic acid 95, in the δ opioid receptor specifies selective high affinity agonist binding. J. Biol. Chem. 268, 23055-23058.
16. Lefkowitz R. J., Cotecchia S., Samama P., and Costa T. (1993) Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins. Trends Pharmacol. Sci. 14, 303-307.
17. Maguire P., Tsai N., Kamal J., Cometta-Morini C., Upton C., and Loew G. (1992) Pharmacological profiles of fentanyl analogs at μ, δ and κ opiate receptors. Eur. J. Pharmacol. 213, 219-225.
18. Mansour A., Taylor L. P., Fine J. L., Thompson R. C., Hoversten M. T., Mosberg H. I., Watson S. J., and Akil H. (1997) Key residues defining the μ-opioid receptor binding pocket: a site-directed mutagenesis study. J. Neurochem. 68, 344-353.
19. Mjanger E. and Yaksh T. L. (1991) Characteristics of dose-dependent antagonism by beta-funaltrexamine of the antinociceptive effects of intrathecal mu agonists. J. Pharmacol. Exp. Ther. 258, 544-550.
20. Negus S. S. and Woods J. H. (1995) Reinforcing effects, discriminative stimulus effects, and physical dependence liability of buprenorphine, in Buprenorphine; Combating Drug Abuse with a Unique Opioid (Cowan A. and Lewis J. W., eds), pp. 71-101. Wiley-Liss, New York.
21. + channel-acting drugs. Br. J. Pharmacol. 114, 1296-1302.
22. Raffa R. B., Connelly C. D., and Martinez R. P. (1992) Opioid efficacy is linked to the LiCl-sensitive, inositol-1,4,5-triphosphate-restorable pathway. Eur. J. Pharmacol. 217, 221-223.
23. Raffa R. B., Martinez R. P., and Connelly C. D. (1994) G-protein antisense oligodeoxyribonucleotides and μ-opioid supraspinal antinociception. Eur. J. Pharmacol. 258, R5-R7.
24. Raynor K., Kong H., Chen Y., Yasuda K., Yu L., Bell G. I., and Reisine T. (1994) Pharmacological characterization of the cloned κ-, δ-, and μ-opioid receptors. Mol. Pharmacol. 45, 330-334.
25. Reisine T. and Bell G. (1993) Molecular biology of the opiate receptors. Trends Neurosci. 16, 506-510.
26. Reisine T. and Pasternak G. (1996) Opioid analgesics and antagonists, in The Pharmacological Basis of Therapeutics, 9th edit. (Hardman J. G., Limbird L. E., Molinoff P. B., Ruddon R. W., and Gilman A. G., eds), pp. 521-555. McGraw-Hill, New York.
27. Saeki S. and Yaksh T. L. (1993) Suppression of nociceptive responses by spinal mu opioid agonists: effects of stimulus intensity and agonist efficacy. Anesth. Analg. 77, 265-274.
28. 2-mediated supraspinal analgesia in mice. Life Sci. 48, 1721-1727.
29. Schuh K. J., Walsh S. L., Bigelow G. E., Preston K. L., and Stitzer M. L. (1996) Buprenorphine, morphine and naloxone effects during ascending morphine maintenance in humans. J. Pharmacol. Exp. Ther. 278, 836-846.
30. Selley D. E., Sim L. J., Xiao R., Liu Q., and Childers S. R. (1996) μ-Opioid receptor stimulated guanosine-5′-O-(γ-thio)-triphosphate binding in rat thalamus and cultured cell lines: signal transduction mechanisms underlying agonist efficacy. Mol. Pharmacol. 51, 87-96.
31. Serturner F. W. A. (1805) Darstellung der reinen Mohnasaure (Opiumsaure); nebst einer chemischen Untersuchung des opiums, mit vorzuglicher Hinsicht auf einen darin neu entdeckten Stoff. J. Pharm. Arzte. Apoth. Chem. 14, 47-93.
32. Stickle D. and Barber R. (1991) Comparison of the combined contributions of agonist binding frequency and intrinsic efficiency to receptor-mediated activation of adenylate cyclase. Mol. Pharmacol. 40, 276-286.
33. Surratt C. K., Johnson P. S., Moriwaki A., Seidleck B. K., Blaschak C. J., Wang J. B., and Uhl G. R. (1994) μ-Opiate receptor: charged transmembrane domain amino acids are critical for agonist recognition and intrinsic activity. J. Biol. Chem. 269, 20548-20553.
34. Toll L. (1995) Intact cell binding and the relation to opioid activities in SH-SY5Y cells. J. Pharmacol. Exp. Ther. 273, 721-727.
35. 35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells. Mol. Pharmacol. 47, 848-854.